drugset / Trial / NCT04842604
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.
Timeline
- Start
- 2021-05-17
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Glasdegib | Small molecule | 50 mg | Oral |
| Subject | Glasdegib | Small molecule | 75 mg | Oral |
| Subject | Glasdegib | Small molecule | 100 mg | Oral |